Journal article
Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it.
Abstract
Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) is rapidly becoming widely accepted as the standard-of-care for imaging of men with prostate cancer. Labeled indications for regulatoryapproved agents include primary staging and recurrent disease in men at risk of metastases. The first commercial PSMA PET agent to become available was 18F-DCFPyL (piflufolastat F 18), a radiofluorinated small molecule with …
Authors
Rowe SP; Voter AF; Werner RA; Zukotynski KA; Pomper MG; Gorin MA; Solnes LB
Journal
Canadian Journal of Urology, Vol. 30, No. 1, pp. 11432–11437
Publication Date
February 2023
ISSN
1195-9479